New experimental and clinical links between the hippocampus and the dopaminergic system in Parkinson's disease

The Lancet Neurology

Volumn 12, Issue 8, 2013, Pages 811-821

  Calabresi, Paolo ^a,b   Castrioto, Anna ^a,c   Di Filippo, Massimiliano ^a   Picconi, Barbara ^b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; GLUCOSYLCERAMIDASE; LEVODOPA; MEMANTINE; NEUROTROPHIC FACTOR; PLACEBO; RIVASTIGMINE;

BASAL GANGLION; BRAIN ATROPHY; COGNITION; DECISION MAKING; DECLARATIVE MEMORY; DENTATE GYRUS; DISEASE ASSOCIATION; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; EXECUTIVE FUNCTION; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HIPPOCAMPAL CA1 REGION; HIPPOCAMPUS; HUMAN; LEARNING; LONG TERM POTENTIATION; MOTIVATION; NERVE CELL PLASTICITY; NONHUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; PREFRONTAL CORTEX; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; VERBAL MEMORY;

ANIMALS; COGNITION DISORDERS; DOPAMINE; DOPAMINERGIC NEURONS; HIPPOCAMPUS; HUMANS; NERVE GROWTH FACTORS; NEURONAL PLASTICITY; PARKINSON DISEASE;

EID: 84880383782     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(13)70118-2     Document Type: Review

References (126)

1. Lees AJ, Hardy J, Revesz T Parkinson's disease. Lancet 2009, 373:2055-2066.
2. Chaudhuri KR, Schapira AH Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009, 8:464-474.
3. Chaudhuri KR, Healy DG, Schapira AH Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006, 5:235-245.
4. Fox SH, Brotchie JM, Lang AE Non-dopaminergic treatments in development for Parkinson's disease. Lancet Neurol 2008, 7:927-938.
5. Halliday G, Lees A, Stern M Milestones in Parkinson's disease-clinical and pathologic features. Mov Disord 2011, 26:1015-1021.
6. Czernecki V, Schupbach M, Yaici S, et al. Apathy following subthalamic stimulation in Parkinson disease: a dopamine responsive symptom. Mov Disord 2008, 23:964-969.
7. Thobois S, Ardouin C, Lhommee E, et al. Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation. Brain 2010, 133:1111-1127.
8. Pavese N, Metta V, Bose SK, Chaudhuri KR, Brooks DJ Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunction. Brain 2010, 133:3434-3443.
9. Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010, 9:573-580.
10. Ballanger B, Klinger H, Eche J, et al. Role of serotonergic 1A receptor dysfunction in depression associated with Parkinson's disease. Mov Disord 2012, 27:84-89.
11. Dagher A, Robbins TW Personality, addiction, dopamine: insights from Parkinson's disease. Neuron 2009, 61:502-510.
12. Kehagia AA, Barker RA, Robbins TW Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurol 2010, 9:1200-1213.
13. Voon V, Fernagut PO, Wickens J, et al. Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders. Lancet Neurol 2009, 8:1140-1149.
14. Lisman J, Grace AA, Duzel E A neoHebbian framework for episodic memory; role of dopamine-dependent late LTP. Trends Neurosci 2011, 34:536-547.
15. Costa C, Sgobio C, Siliquini S, et al. Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson's disease. Brain 2012, 135:1884-1899.
16. Lisman JE, Grace AA The hippocampal-VTA loop: controlling the entry of information into long-term memory. Neuron 2005, 46:703-713.
17. Adcock RA, Thangavel A, Whitfield-Gabrieli S, Knutson B, Gabrieli JD Reward-motivated learning: mesolimbic activation precedes memory formation. Neuron 2006, 50:507-517.
18. Pessiglione M, Seymour B, Flandin G, Dolan RJ, Frith CD Dopamine-dependent prediction errors underpin reward-seeking behaviour in humans. Nature 2006, 442:1042-1045.
19. Wittmann BC, Schott BH, Guderian S, Frey JU, Heinze HJ, Duzel E Reward-related FMRI activation of dopaminergic midbrain is associated with enhanced hippocampus-dependent long-term memory formation. Neuron 2005, 45:459-467.
20. Johnson A, van der Meer MA, Redish AD Integrating hippocampus and striatum in decision-making. Curr Opin Neurobiol 2007, 17:692-697.
21. Shohamy D, Adcock RA Dopamine and adaptive memory. Trends Cogn Sci 2010, 14:464-472.
22. Ghiglieri V, Sgobio C, Costa C, Picconi B, Calabresi P Striatum-hippocampus balance: from physiological behavior to interneuronal pathology. Prog Neurobiol 2011, 94:102-114.
23. Rodriguez-Oroz MC, Jahanshahi M, Krack P, et al. Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms. Lancet Neurol 2009, 8:1128-1139.
24. Svenningsson P, Westman E, Ballard C, Aarsland D Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment. Lancet Neurol 2012, 11:697-707.
25. Pennartz CM, Ito R, Verschure PF, Battaglia FP, Robbins TW The hippocampal-striatal axis in learning, prediction and goal-directed behavior. Trends Neurosci 2011, 34:548-559.
26. Benardo LS, Prince DA Dopamine action on hippocampal pyramidal cells. J Neurosci 1982, 2:415-423.
27. Stanzione P, Calabresi P, Mercuri N, Bernardi G Dopamine modulates CA1 hippocampal neurons by elevating the threshold for spike generation: an in vitro study. Neuroscience 1984, 13:1105-1116.
28. Berretta N, Berton F, Bianchi R, Capogna M, Francesconi W, Brunelli M Effects of dopamine, D-1 and D-2 dopaminergic agonists on the excitability of hippocampal CA1 pyramidal cells in guinea pig. Exp Brain Res 1990, 83:124-130.
29. Hammad H, Wagner JJ Dopamine-mediated disinhibition in the CA1 region of rat hippocampus via D3 receptor activation. J Pharmacol Exp Ther 2006, 316:113-120.
30. Noriyama Y, Ogawa Y, Yoshino H, Yamashita M, Kishimoto T Dopamine profoundly suppresses excitatory transmission in neonatal rat hippocampus via phosphatidylinositol-linked D1-like receptor. Neuroscience 2006, 138:475-485.
31. Kobayashi K, Suzuki H Dopamine selectively potentiates hippocampal mossy fiber to CA3 synaptic transmission. Neuropharmacology 2007, 52:552-561.
32. Knecht S, Breitenstein C, Bushuven S, et al. Levodopa: faster and better word learning in normal humans. Ann Neurol 2004, 56:20-26.
33. Goto Y, Grace AA Dopaminergic modulation of limbic and cortical drive of nucleus accumbens in goal-directed behavior. Nat Neurosci 2005, 8:805-812.
34. Goto Y, Grace AA Dopamine-dependent interactions between limbic and prefrontal cortical plasticity in the nucleus accumbens: disruption by cocaine sensitization. Neuron 2005, 47:255-266.
35. Grace AA Physiology of the normal and dopamine-depleted basal ganglia: insights into levodopa pharmacotherapy. Mov Disord 2008, 23(suppl 3):S560-S569.
36. Frank MJ, Seeberger LC, O'Reilly RC By carrot or by stick: cognitive reinforcement learning in parkinsonism. Science 2004, 306:1940-1943.
37. Schultz W Getting formal with dopamine and reward. Neuron 2002, 36:241-263.
38. Grace AA, Floresco SB, Goto Y, Lodge DJ Regulation of firing of dopaminergic neurons and control of goal-directed behaviors. Trends Neurosci 2007, 30:220-227.
39. Foerde K, Shohamy D Feedback timing modulates brain systems for learning in humans. J Neurosci 2011, 31:13157-13167.
40. Goto Y, Grace AA Limbic and cortical information processing in the nucleus accumbens. Trends Neurosci 2008, 31:552-558.
41. Pierce RC, Kalivas PW A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res Brain Res Rev 1997, 25:192-216.
42. Robinson TE, Berridge KC The psychology and neurobiology of addiction: an incentive-sensitization view. Addiction 2000, 95(suppl 2):S91-117.
43. Voon V, Gao J, Brezing C, et al. Dopamine agonists and risk: impulse control disorders in Parkinson's disease. Brain 2011, 134:1438-1446.
44. Voon V, Mehta AR, Hallett M Impulse control disorders in Parkinson's disease: recent advances. Curr Opin Neurol 2011, 24:324-330.
45. Voon V, Sohr M, Lang AE, et al. Impulse control disorders in Parkinson disease: a multicenter case-control study. Ann Neurol 2011, 69:986-996.
46. Lhommee E, Klinger H, Thobois S, et al. Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours. Brain 2012, 135:1463-1477.
47. Evans AH, Pavese N, Lawrence AD, et al. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol 2006, 59:852-858.
48. O'Sullivan SS, Wu K, Politis M, et al. Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours. Brain 2011, 134:969-978.
49. Steeves TD, Miyasaki J, Zurowski M, et al. Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. Brain 2009, 132:1376-1385.
50. Cilia R, Siri C, Marotta G, et al. Functional abnormalities underlying pathological gambling in Parkinson disease. Arc Neurol 2008, 65:1604-1611.
51. Lodge DJ, Grace AA Hippocampal dysregulation of dopamine system function and the pathophysiology of schizophrenia. Trends Pharmacol Sci 2011, 32:507-513.
52. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008, 23:837-844.
53. Aarsland D, Bronnick K, Larsen JP, Tysnes OB, Alves G Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. Neurology 2009, 72:1121-1126.
54. Cools R, Altamirano L, D'Esposito M Reversal learning in Parkinson's disease depends on medication status and outcome valence. Neuropsychologia 2006, 44:1663-1673.
55. Cools R, Barker RA, Sahakian BJ, Robbins TW Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands. Cereb Cortex 2001, 11:1136-1143.
56. Cools R, Lewis SJ, Clark L, Barker RA, Robbins TW L-DOPA disrupts activity in the nucleus accumbens during reversal learning in Parkinson's disease. Neuropsychopharmacology 2007, 32:180-189.
57. Swainson R, Rogers RD, Sahakian BJ, Summers BA, Polkey CE, Robbins TW Probabilistic learning and reversal deficits in patients with Parkinson's disease or frontal or temporal lobe lesions: possible adverse effects of dopaminergic medication. Neuropsychologia 2000, 38:596-612.
58. van Wouwe NC, Ridderinkhof KR, Band GP, van den Wildenberg WP, Wylie SA Dose dependent dopaminergic modulation of reward-based learning in Parkinson's disease. Neuropsychologia 2012, 50:583-591.
59. Churchyard A, Lees AJ The relationship between dementia and direct involvement of the hippocampus and amygdala in Parkinson's disease. Neurology 1997, 49:1570-1576.
60. Laakso MP, Partanen K, Riekkinen P, et al. Hippocampal volumes in Alzheimer's disease, Parkinson's disease with and without dementia, and in vascular dementia: an MRI study. Neurology 1996, 46:678-681.
61. Riekkinen P, Kejonen K, Laakso MP, Soininen H, Partanen K, Riekkinen M Hippocampal atrophy is related to impaired memory, but not frontal functions in non-demented Parkinson's disease patients. Neuroreport 1998, 9:1507-1511.
62. Camicioli R, Moore MM, Kinney A, Corbridge E, Glassberg K, Kaye JA Parkinson's disease is associated with hippocampal atrophy. Mov Disord 2003, 18:784-790.
63. Bruck A, Kurki T, Kaasinen V, Vahlberg T, Rinne JO Hippocampal and prefrontal atrophy in patients with early non-demented Parkinson's disease is related to cognitive impairment. J Neurol Neurosurg Psychiatry 2004, 75:1467-1469.
64. Tam CW, Burton EJ, McKeith IG, Burn DJ, O'Brien JT Temporal lobe atrophy on MRI in Parkinson disease with dementia: a comparison with Alzheimer disease and dementia with Lewy bodies. Neurology 2005, 64:861-865.
65. Ibarretxe-Bilbao N, Ramirez-Ruiz B, Tolosa E, et al. Hippocampal head atrophy predominance in Parkinson's disease with hallucinations and with dementia. J Neurol 2008, 255:1324-1331.
66. Bouchard TP, Malykhin N, Martin WR, et al. Age and dementia-associated atrophy predominates in the hippocampal head and amygdala in Parkinson's disease. Neurobiol Aging 2008, 29:1027-1039.
67. Jokinen P, Bruck A, Aalto S, Forsback S, Parkkola R, Rinne JO Impaired cognitive performance in Parkinson's disease is related to caudate dopaminergic hypofunction and hippocampal atrophy. Parkinsonism Relat Disord 2009, 15:88-93.
68. Jokinen P, Scheinin N, Aalto S, et al. [(11)C]PIB-,[(18)F]FDG-PET and MRI imaging in patients with Parkinson's disease with and without dementia. Parkinsonism Relat Disord 2010, 16:666-670.
69. Weintraub D, Dietz N, Duda JE, et al. Alzheimer's disease pattern of brain atrophy predicts cognitive decline in Parkinson's disease. Brain 2012, 135:170-180.
70. Apostolova LG, Beyer M, Green AE, et al. Hippocampal, caudate, and ventricular changes in Parkinson's disease with and without dementia. Mov Disord 2010, 25:687-695.
71. Carlesimo GA, Piras F, Assogna F, Pontieri FE, Caltagirone C, Spalletta G Hippocampal abnormalities and memory deficits in Parkinson disease: a multimodal imaging study. Neurology 2012, 78:1939-1945.
72. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. NEngl J Med 2004, 351:2509-2518.
73. Ballard C, Kahn Z, Corbett A Treatment of dementia with Lewy bodies and Parkinson's disease dementia. Drug Aging 2011, 28:769-777.
74. Emre M, Tsolaki M, Bonuccelli U, et al. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010, 9:969-977.
75. Sugisaki E, Fukushima Y, Tsukada M, Aihara T Cholinergic modulation on spike timing-dependent plasticity in hippocampal CA1 network. Neuroscience 2011, 192:91-101.
76. Klyubin I, Wang Q, Reed MN, et al. Protection against Abeta-mediated rapid disruption of synaptic plasticity and memory by memantine. Neurobiol Aging 2011, 32:614-623.
77. Morley JF, Weintraub D, Mamikonyan E, Moberg PJ, Siderowf AD, Duda JE Olfactory dysfunction is associated with neuropsychiatric manifestations in Parkinson's disease. Mov Disord 2011, 26:2051-2057.
78. Bohnen NI, Gedela S, Herath P, Constantine GM, Moore RY Selective hyposmia in Parkinson disease: association with hippocampal dopamine activity. Neurosci Lett 2008, 447:12-16.
79. Bohnen NI, Muller ML, Kotagal V, et al. Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson's disease. Brain 2010, 133:1747-1754.
80. Hansen N, Manahan-Vaughan D Dopamine D1/D5 receptors mediate informational saliency that promotes persistent hippocampal long-term plasticity. Cereb Cortex 2012, published online Nov 25. 10.1093/cercor/bhs362.
81. Bliss TV, Lomo T Long-lasting potentiation of synaptic transmission in the dentate area of the anaesthetized rabbit following stimulation of the perforant path. J Physiol 1973, 232:331-356.
82. Bliss TV, Collingridge GL A synaptic model of memory: long-term potentiation in the hippocampus. Nature 1993, 361:31-39.
83. Frey U, Matthies H, Reymann KG, Matthies H The effect of dopaminergic D1 receptor blockade during tetanization on the expression of long-term potentiation in the rat CA1 region in vitro. Neurosci Lett 1991, 129:111-114.
84. Huang YY, Kandel ER D1/D5 receptor agonists induce a protein synthesis-dependent late potentiation in the CA1 region of the hippocampus. Proc Natl Acad Sci USA 1995, 92:2446-2450.
85. Otmakhova NA, Lisman JE D1/D5 dopamine receptor activation increases the magnitude of early long-term potentiation at CA1 hippocampal synapses. J Neurosci 1996, 16:7478-7486.
86. Granado N, Ortiz O, Suarez LM, et al. D1 but not D5 dopamine receptors are critical for LTP, spatial learning, and LTP-Induced arc and zif268 expression in the hippocampus. Cereb Cortex 2008, 18:1-12.
87. Lemon N, Manahan-Vaughan D Dopamine D1/D5 receptors gate the acquisition of novel information through hippocampal long-term potentiation and long-term depression. J Neurosci 2006, 26:7723-7729.
88. Kusuki T, Imahori Y, Ueda S, Inokuchi K Dopaminergic modulation of LTP induction in the dentate gyrus of intact brain. Neuroreport 1997, 8:2037-2040.
89. Swanson-Park JL, Coussens CM, Mason-Parker SE, et al. A double dissociation within the hippocampus of dopamine D1/D5 receptor and beta-adrenergic receptor contributions to the persistence of long-term potentiation. Neuroscience 1999, 92:485-497.
90. Yanagihashi R, Ishikawa T Studies on long-term potentiation of the population spike component of hippocampal field potential by the tetanic stimulation of the perforant path rats: effects of a dopamine agonist, SKF-38393. Brain Res 1992, 579:79-86.
91. Hamilton TJ, Wheatley BM, Sinclair DB, Bachmann M, Larkum ME, Colmers WF Dopamine modulates synaptic plasticity in dendrites of rat and human dentate granule cells. Proc Natl Acad Sci USA 2010, 107:18185-18190.
92. Smith CC, Greene RW CNS dopamine transmission mediated by noradrenergic innervation. J Neurosci 2012, 32:6072-6080.
93. Del Tredici K, Braak H Dysfunction of the locus coeruleus-norepinephrine system and related circuitry in Parkinson's disease-related dementia. J Neurol Neurosurg Psychiatry 2012, 84:774-783.
94. Navakkode S, Sajikumar S, Korte M, Soong TW Dopamine induces LTP differentially in apical and basal dendrites through BDNF and voltage-dependent calcium channels. Learn Mem 2012, 19:294-299.
95. Goedert M, Spillantini MG, Del Tredici K, Braak H 100 years of Lewy pathology. Nat Rev Neurol 2012, 9:13-24.
96. Vekrellis K, Xilouri M, Emmanouilidou E, Rideout HJ, Stefanis L Pathological roles of alpha-synuclein in neurological disorders. Lancet Neurol 2011, 10:1015-1025.
97. Tofaris GK, Garcia Reitbock P, Humby T, et al. Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120): implications for Lewy body disorders. J Neurosci 2006, 26:3942-3950.
98. Diogenes MJ, Dias RB, Rombo DM, et al. Extracellular alpha-synuclein oligomers modulate synaptic transmission and impair LTP via NMDA-receptor activation. J Neurosci 2012, 32:11750-11762.
99. Kelly BL, Ferreira A beta-Amyloid-induced dynamin 1 degradation is mediated by N-methyl-D-aspartate receptors in hippocampal neurons. J Biol Chem 2006, 281:28079-28089.
100. Greengard P, Allen PB, Nairn AC Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade. Neuron 1999, 23:435-447.
101. Martin ZS, Neugebauer V, Dineley KT, et al. alpha-Synuclein oligomers oppose long-term potentiation and impair memory through a calcineurin-dependent mechanism: relevance to human synucleopathic diseases. J Neurochem 2012, 120:440-452.
102. Volpicelli-Daley LA, Luk KC, Patel TP, et al. Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 2011, 72:57-71.
103. Lim Y, Kehm VM, Lee EB, et al. alpha-Syn suppression reverses synaptic and memory defects in a mouse model of dementia with Lewy bodies. J Neurosci 2011, 31:10076-10087.
104. Sidransky E, Lopez G The link between the GBA gene and parkinsonism. Lancet Neurol 2012, 11:986-998.
105. Sardi SP, Clarke J, Kinnecom C CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy. Proc Natl Acad Sci USA 2011, 108:12101-12106.
106. Sardi SP, Clarke J, Viel C, et al. Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies. Proc Natl Acad Sci USA 2013, 110:3537-3542.
107. Nielsen MS, Sorensen JC, Bjarkam CR The substantia nigra pars compacta of the Gottingen minipig: an anatomical and stereological study. Brain Struct Funct 2009, 213:481-488.
108. Pan-Montojo F, Anichtchik O, Dening Y, et al. Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice. PLoS One 2010, 5:e8762.
109. Eisch AJ, Petrik D Depression and hippocampal neurogenesis: a road to remission?. Science 2012, 338:72-75.
110. Veena J, Rao BS, Srikumar BN Regulation of adult neurogenesis in the hippocampus by stress, acetylcholine and dopamine. J Nat Sci Biol Med 2011, 2:26-37.
111. Aron L, Klein R Repairing the parkinsonian brain with neurotrophic factors. Trends Neurosci 2011, 34:88-100.
112. Leal G, Comprido D, Duarte CB BDNF-induced local protein synthesis and synaptic plasticity. Neuropharmacology 2013, published online April 16. 10.1016/j.neuropharm.2013.04.005.
113. Chen Y, Ai Y, Slevin JR, Maley BE, Gash DM Progenitor proliferation in the adult hippocampus and substantia nigra induced by glial cell line-derived neurotrophic factor. Exp Neurol 2005, 196:87-95.
114. Boscia F, Esposito CL, Di Crisci A, de Franciscis V, Annunziato L, Cerchia L GDNF selectively induces microglial activation and neuronal survival in CA1/CA3 hippocampal regions exposed to NMDA insult through Ret/ERK signalling. PLoS One 2009, 4:e6486.
115. Kohl Z, Winner B, Ubhi K, et al. Fluoxetine rescues impaired hippocampal neurogenesis in a transgenic A53T synuclein mouse model. Eur J Neurosci 2012, 35:10-19.
116. Antonini A, Tolosa E, Mizuno Y, Yamamoto M, Poewe WH A reassessment of risks and benefits of dopamine agonists in Parkinson's disease. Lancet Neurol 2009, 8:929-937.
117. Robbins TW, Arnsten AF The neuropsychopharmacology of fronto-executive function: monoaminergic modulation. Annu Rev Neurosci 2009, 32:267-287.
118. Bergson C, Mrzljak L, Smiley JF, Pappy M, Levenson R, Goldman-Rakic PS Regional, cellular, and subcellular variations in the distribution of D1 and D5 dopamine receptors in primate brain. J Neurosci 1995, 15:7821-7836.
119. Bethus I, Tse D, Morris RG Dopamine and memory: modulation of the persistence of memory for novel hippocampal NMDA receptor-dependent paired associates. J Neurosci 2010, 30:1610-1618.
120. Gangarossa G, Longueville S, De Bundel D, et al. Characterization of dopamine D1 and D2 receptor-expressing neurons in the mouse hippocampus. Hippocampus 2012, 22:2199-2207.
121. Delgado MR, Dickerson KC Reward-related learning via multiple memory systems. Biol Psychiatry 2012, 72:134-141.
122. Calabresi P, Filippo MD, Ghiglieri V, Tambasco N, Picconi B Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap. Lancet Neurol 2010, 9:1106-1117.
123. Calabresi P, Picconi B, Parnetti L, Di Filippo M A convergent model for cognitive dysfunctions in Parkinson's disease: the critical dopamine-acetylcholine synaptic balance. Lancet Neurol 2006, 5:974-983.
124. Calabresi P, Picconi B, Tozzi A, Di Filippo M Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends Neurosci 2007, 30:211-219.
125. Picconi B, Centonze D, Hakansson K, et al. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci 2003, 6:501-506.
126. Shohamy D, Myers CE, Hopkins RO, Sage J, Gluck MA Distinct hippocampal and basal ganglia contributions to probabilistic learning and reversal. J Cogn Neurosci 2009, 21:1821-1833.